Whitebox Advisors Llc decreased New Residential Invt Corp (NRZ) stake by 65.95% reported in 2017Q2 SEC filing. Whitebox Advisors Llc sold 1.61 million shares as New Residential Invt Corp (NRZ)’s stock declined 0.74%. The Whitebox Advisors Llc holds 828,668 shares with $12.89M value, down from 2.43 million last quarter. New Residential Invt Corp now has $5.51 billion valuation. The stock increased 0.06% or $0.01 during the last trading session, reaching $17.94. About 1.48 million shares traded. New Residential Investment Corp. (NYSE:NRZ) has risen 22.04% since December 10, 2016 and is uptrending. It has outperformed by 5.34% the S&P500.
Pernix Therapeutics Holdings Incorporated (NASDAQ:PTX) had an increase of 1.94% in short interest. PTX’s SI was 1.64M shares in December as released by FINRA. Its up 1.94% from 1.61 million shares previously. With 51,100 avg volume, 32 days are for Pernix Therapeutics Holdings Incorporated (NASDAQ:PTX)’s short sellers to cover PTX’s short positions. The SI to Pernix Therapeutics Holdings Incorporated’s float is 19.12%. The stock decreased 1.52% or $0.04 during the last trading session, reaching $2.6. About 78,317 shares traded. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has risen 9.00% since December 10, 2016 and is uptrending. It has underperformed by 7.70% the S&P500.
Among 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Pernix Therapeutics had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, March 11 by Needham. The firm has “Buy” rating by Brean Capital given on Friday, August 7. The firm earned “Buy” rating on Friday, March 11 by Brean Capital. The firm has “Perform” rating by Oppenheimer given on Thursday, March 17. Brean Capital maintained the shares of PTX in report on Tuesday, February 9 with “Buy” rating. Brean Capital downgraded the stock to “Hold” rating in Friday, August 12 report. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, September 9. Needham maintained the stock with “Strong Buy” rating in Friday, August 7 report.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. The company has market cap of $30.27 million. It targets underserved therapeutic areas, such as central nervous system , including neurology, pain, and psychiatry. It currently has negative earnings. The companyÂ’s products comprise Treximet, a fixed dose combination product indicated for the treatment of acute migraine; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; and Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance.
Analysts await New Residential Investment Corp. (NYSE:NRZ) to report earnings on February, 20. They expect $0.49 EPS, down 20.97% or $0.13 from last year’s $0.62 per share. NRZ’s profit will be $150.61 million for 9.15 P/E if the $0.49 EPS becomes a reality. After $0.64 actual EPS reported by New Residential Investment Corp. for the previous quarter, Wall Street now forecasts -23.44% negative EPS growth.
Among 8 analysts covering New Residential Investment Corp (NYSE:NRZ), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. New Residential Investment Corp had 22 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Sell” rating given on Wednesday, August 12 by Zacks. The stock of New Residential Investment Corp. (NYSE:NRZ) earned “Buy” rating by Piper Jaffray on Sunday, August 27. The rating was initiated by Nomura on Wednesday, October 26 with “Neutral”. Piper Jaffray maintained the shares of NRZ in report on Thursday, October 26 with “Buy” rating. The rating was upgraded by Piper Jaffray to “Overweight” on Monday, October 19. The stock of New Residential Investment Corp. (NYSE:NRZ) has “Buy” rating given on Tuesday, June 6 by Keefe Bruyette & Woods. Wedbush initiated New Residential Investment Corp. (NYSE:NRZ) rating on Thursday, October 6. Wedbush has “Outperform” rating and $17 target. The firm earned “Buy” rating on Wednesday, November 29 by FBR Capital. The rating was maintained by FBR Capital on Friday, June 23 with “Buy”. The stock of New Residential Investment Corp. (NYSE:NRZ) earned “Buy” rating by Keefe Bruyette & Woods on Tuesday, September 12.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.